Clinical Trials Logo

Eczema clinical trials

View clinical trials related to Eczema.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06412094 Completed - Atopic Dermatitis Clinical Trials

Use of a Mobile Health App in Managing Pediatric Atopic Dermatitis

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

A randomized controlled study in children with AD, divided into three groups: a control group without access to the app, an experimental observational group with the app, and an experimental interventional group with potential investigator supervision. Outcome measures included the SCORAD and the POEM scores.

NCT ID: NCT06380647 Completed - Clinical trials for Herpes Virus Infection

Comparison of Prophylactic Acyclovir and Placebo in Prevention of Eczema Herpeticum in Pediatric Burns

childburn
Start date: October 1, 2019
Phase: N/A
Study type: Interventional

Introduction: Early detection is important in treating patients with Eczema Herpeticum (EH), which may arise in paediatric burn patients. As soon as a clinical diagnosis is confirmed, antiviral medications should be started to ensure an early resolution of the disease. Several studies have indicated that acyclovir is the best treatment for EH lesions in the majority of individuals. Objective: Compare efficacy of the prophylactic acyclovir and placebo in preventing eczema Herpeticum in paediatric burn patients

NCT ID: NCT06361992 Completed - Atopic Dermatitis Clinical Trials

Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children

Start date: March 15, 2022
Phase: Phase 3
Study type: Interventional

To verify the efficacy and tolerability of Activated Piroctone Olamine (Blue Cap Foam, label volume 100 ml) by CATALYSIS, S. L. Madrid, applied in the management of all types of dermatitis (atopic, seborrheic, eczema) in patients with significant manifestations of the disease in varying areas of the body of varying extent and to assess differences in individual tolerability and the final effect in a group of selected patients aged 3 to 18 years.

NCT ID: NCT06085521 Completed - Atopic Dermatitis Clinical Trials

A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis

Start date: January 26, 2022
Phase: Phase 2
Study type: Interventional

Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice daily oral LNK01001 dose A or LNK01001 dose B or matching placebo for 12 weeks.

NCT ID: NCT06035835 Completed - Atopic Dermatitis Clinical Trials

Probiotics and Breastmilk Decrease Risk of Atopic Dermatitis in Premature Infants

Start date: January 1, 2009
Phase:
Study type: Observational

The purpose of this study is assess if the use of probiotic in very low weight could be other benefits a long time, as reduce atopic disease in this children.

NCT ID: NCT05918237 Completed - Clinical trials for Atopic Dermatitis Eczema

Pilot Study to Test the Effects of Arctiva on Mild to Moderate Eczema

Start date: February 6, 2023
Phase: N/A
Study type: Interventional

Up to 30 participants with mild to moderate atopic dermatitis/eczema will be enrolled to apply study Investigational Product for 4 weeks.

NCT ID: NCT05904509 Completed - Atopic Dermatitis Clinical Trials

Insulin Resistance in Atopic Dermatitis Patients

Start date: September 1, 2022
Phase:
Study type: Observational

The aim of the study is to determine the relationship between insulin resistance and disease duration and severity of atopic dermatitis.

NCT ID: NCT05833880 Completed - Atopic Dermatitis Clinical Trials

Use of Complementary and Alternative Medicine in Children and Adults With Atopic Dermatitis

Start date: May 10, 2023
Phase:
Study type: Observational

Complementary and alternative medicine are increasingly used all around the world and more specifically in chronic diseases such as atopic dermatitis. Sociodemographic and disease determinants associated with their use remain unclear. Moreover, most of studies involved children and little data are available for adults. The main objective of this study is to identify factors associated with complementary and alternative medicine use in children and adults suffering from atopic dermatitis. The secondary objectives are to determine the prevalence of complementary and alternative medicine use, the main forms used and their modalities of use, patients' motivations for using these therapies and sources of information. Patients of all ages consulting for their atopic dermatitis at the dermatology or pediatric allergology department of Nancy University Hospital over a 6 months period will be asked to fill out a questionnaire about their pathology and their use of complementary and alternative medicine. This questionnaire will be collected before they leave the hospital.

NCT ID: NCT05783453 Completed - Atopic Dermatitis Clinical Trials

CLINICAL EFFICACY OF EMOLLIENTS IN ATOPIC DERMATITIS PATIENTS

Start date: December 20, 2021
Phase:
Study type: Observational

his was a monocentric, intra-individual study, that was performed in at least 45 valid cases (50% children ≥3 YO; 50% adults). Study duration was 168 days with five (5) visits (D0, D14, D28, D84 and D168) to the research center. Primary objective - Evaluation of the efficacy of LIPIKAR BAUME LIGHT AP+M in decrease the SCORAD in child and adult subjects with mild atopic dermatitis after 14 and 28 days under normal conditions of use; - Evaluation of the efficacy of LIPIKAR BAUME LIGHT AP+M in maintenance the SCORAD value in child and adult subjects with mild atopic dermatitis after 84 and 168 days under normal conditions of use. Secondary objective - Evaluation of flares quantity and severity during 84 and 168 days of use; - Clinical evaluation of the improvement of skin parameters such as erythema, oedema, oozing, excoriation, lichenification, dryness and desquamation of a lesional and non-lesional skin from the same individual site by dermatologist after 14, 28, 84 and 168 days; - Self-assessment of the improvement of skin parameters such as itching, tingling, burning by subjects after 14, 28, 84 and 168 days; - Evaluate the perceived efficacy, cosmeticity and acceptability through a subjective evaluation questionnaire after 14, 28, 84 and 168 days; - Evaluation of the improvement in skin barrier function by the loss of transepidermic water through instrumental measurements with the Tewameter® equipment on AF and UAF after 14, 28, 84 and 168 days; - Evaluation of the improvement of skin moisturizing through instrumental measurements with Corneometer® equipment on AF and UAF after 14, 28, 84 and 168 days; - The folliculitis incidence after 14, 28, 84 and 168 days; - Assessment of the improvement of the impact of quality of life through a DLQI (Dermatology Life Quality Index) questionnaire after 14, 28, 84 and 168 days; - Assessment of global tolerance through clinical dermatological evaluation and reports performed by the subjects after using the product after 14, 28, 84 and 168 days. - Evaluation of total body skin dryness improvement after 14, 28, 84 and 168 days. - Illustrative clinical pictures of one or two affected areas.

NCT ID: NCT05770271 Completed - Psoriasis Clinical Trials

The Novel Electrolyzed Water Spray Treatment Mild Senile Groin Eczema, Neurodermatitis and Psoriasis

Start date: January 29, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to test whether spraying the itching of inflammation skin and groin patients by use of the novel electrolyzed water spray will produce improvement in the condition of itching.